Skip to content

Investor Relations / Press Releases

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary Additional Formats
Toggle Summary Amarin to Present at the 2019 BMO Prescription For Success Healthcare Conference
BEDMINSTER, N.J. and DUBLIN, Ireland, June 18, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
View HTML
Toggle Summary Amarin to Present Findings Regarding Challenges of Current Treatment Options in Reducing Cardiovascular Risks for Diabetes Patients, Even for Those With Controlled Cholesterol Levels, at Annual American Diabetes Association (ADA) Meeting
Approximately 10 Million People with Diabetes Are at Elevated Risk of  Cardiovascular Disease 1,2 In a release issued under the same headline earlier today by  Amarin Corporation plc (NASDAQ: AMRN), please note the copy has been updated to directly focus on Amarin’s presentations for the 2019 ADA
View HTML
Toggle Summary Amarin to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
BEDMINSTER, N.J. and DUBLIN, Ireland, June 04, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
View HTML
Toggle Summary Pharmaceutical Industry Veteran Gwen Fisher Joins Amarin to Lead Corporate Communications
BEDMINSTER, N.J. and DUBLIN, Ireland, May 30, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that Gwen Fisher has joined the company in a newly created role as vice president of Corporate
View HTML
Toggle Summary Amarin to Present at the Jefferies 2019 Healthcare Conference
BEDMINSTER, N.J., and DUBLIN, Ireland, May 30, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
View HTML
Toggle Summary U.S. FDA Grants Priority Review for Vascepa® (Icosapent Ethyl) Supplemental New Drug Application Seeking Cardiovascular Risk Reduction Indication
 - PDUFA date assigned is September 28, 2019, four months sooner than expected  - Vascepa , assuming approval, will be first drug indicated to reduce residual cardiovascular risk in patients with statin-managed LDL-C cholesterol, but persistent elevated triglycerides, as studied in the landmark
View HTML
Toggle Summary Vascepa® to Be Featured in Multiple Scientific Sessions at the National Lipid Association Annual Meeting
Vascepa’s REDUCE-IT Trial Impact on Clinical Practice an Important Highlight BEDMINSTER, N.J. and DUBLIN, Ireland, May 16, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that Vascepa® (icosapent
View HTML
Toggle Summary Amarin Reports First Quarter 2019 Financial Results and Provides Update on Operations
Total Revenue Increased 67% to $73.3 Million in First Quarter 2019 Compared to Prior Year Management to Host Conference Call at 7:30 a.m. ET Today BEDMINSTER, N.J., and DUBLIN, Ireland, May 01, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on
View HTML
Toggle Summary New Drug Submission Filed for Vascepa® with Health Canada
BEDMINSTER, N.J., and DUBLIN, Ireland, April 29, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that its licensee in Canada, HLS Therapeutics Inc. (TSX:HLS), has filed a New Drug Submission (“NDS”)
View HTML
Toggle Summary Amarin To Report First Quarter 2019 Results and Host Conference Call On May 1, 2019
BEDMINSTER, N.J. and DUBLIN, Ireland, April 24, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's
View HTML

Amarin Corporation